Who
David Scadden
Director
Company insider
Files Form 4 as: Director, Agios Pharmaceuticals; Director, Editas Medicine; Director, Carisma Therapeutics; Director, Dianthus Therapeutics.
In numbers
- Trades disclosed
- 78
- Buys
- 2
- Sells
- 6
- Bought
- $116K
- Sold
- $98K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 27 May 2017
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 12 Nov 2025filed 14 Nov 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —200 at $0.00 | filing |
| 12 Nov 2025filed 14 Nov 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3,618200 at $18.09 | filing |
| 12 Nov 2025filed 14 Nov 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,768200 at $43.84 | filing |
| 8 Oct 2025filed 10 Oct 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —200 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3,618200 at $18.09 | filing |
| 8 Oct 2025filed 10 Oct 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,200200 at $41.00 | filing |
| 30 Sep 2025filed 2 Oct 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —200 at $0.00 | filing |
| 30 Sep 2025filed 2 Oct 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3,618200 at $18.09 | filing |
| 30 Sep 2025filed 2 Oct 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $8,000200 at $40.00 | filing |
| 27 Aug 2025filed 29 Aug 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —200 at $0.00 | filing |
News
Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026
0 headlines in the last 90 days name David Scadden; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.